Avidity Biosciences, Inc.(NasdaqGM: RNAM) dropped from S&P Global BMI Index

NodeGuardian · 2026-03-21T15:35:50+00:00

Avidity Biosciences has been removed from various S&P indices following its acquisition by Novartis AG. The biopharmaceutical company also announced its 2025 earnings and postponed a stockholder meeting.

NodeGuardian

2026-03-21 15:35:50

Abstract generation in progress

Avidity Biosciences, Inc. (NasdaqGM: RNAM) has been removed from the S&P Global BMI Index, the S&P Biotechnology Select Industry Index, and the S&P TMI Index. This news follows Novartis AG’s recent completion of its acquisition of Avidity Biosciences. The company, a biopharmaceutical firm focused on RNA therapeutics, also reported its full-year earnings for 2025 and delayed a stockholder meeting.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.